Physician profile
Marie Pirillo
NPI 1073593141
$13,876.17
in general payments reported to CMS, 2019-2025
29 companies · $2,287 in 2025
The $2,287 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,368 · 2022: $4,107 · 2023: $2,870 · 2024: $2,244 · 2025: $2,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,126 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,125.97 |
| Education | $274.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,515.26 | 2021-2025 | |
| Janssen Biotech, INC. | $2,188.01 | 2021-2025 | Tremfya, Stelara, Simponi |
| Merz North America, INC. | $1,438.22 | 2021-2025 | Xeomin |
| Novartis Pharmaceuticals Corporation | $1,204.77 | 2021-2025 | |
| Amgen INC. | $1,145.90 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $642.47 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $625.94 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $583.37 | 2021-2025 | Winlevi |
| Galderma Laboratories, L.P. | $568.25 | 2021-2025 | Nemluvio, Twyneo, Aklief |
| Genzyme Corporation | $367.99 | 2022-2025 | |
| Leo Pharma INC. | $347.63 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $284.85 | 2022-2024 | Vtama |
| Pfizer INC. | $279.14 | 2021-2024 | |
| Journey Medical Corporation | $257.27 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $243.36 | 2023-2025 | Ycanth |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $201.61 | 2021-2022 | |
| Lilly USA, LLC | $162.82 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $155.59 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $151.20 | 2021-2025 | Dupixent |
| Biofrontera INC. | $150.42 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $123.53 | 2021-2025 | |
| Epi Health, LLC | $57.05 | 2021-2022 | |
| Almirall LLC | $40.75 | 2022-2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $39.09 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $30.38 | 2021 | |
| Genentech USA, INC. | $22.53 | 2023 | Xolair |
| Sandoz INC. | $17.97 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.49 | 2021 | |
| Mission Pharmacal Company | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Pirillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.